Ambagon Therapeutics is a biotechnology company that is developing cancer molecule therapeutics. The company has offices in San Carlos, California, and Eindhoven, the Netherlands. On Thursday, it announced that it has raised $85M (approx €75.1M) in its Series A round of funding.
The round was led by Nextech Invest. Ambagon’s existing investors RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital also participated in the round along with new investor Surveyor Capital (a Citadel company).